Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth M Gaughan

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal for Immunotherapy of Cancer|September 13, 2022
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)Rick Daniel Vavolizza, Gina R Petroni, Ileana S Mauldin, et al.
Oncoimmunology|April 2, 2021
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanomaCraig L Slingluff, Hassane M Zarour, Hussein Abdul-Hassan Tawbi, et al.
Journal for Immunotherapy of Cancer|January 22, 2021
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)Craig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)Emily K Ninmer, Gina R Petroni, Brian R Gastman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic MelanomaDouglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.
Journal for Immunotherapy of Cancer|March 5, 2026
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review studyElizabeth M Gaughan, Miso Kim, Ignacio Mendez, et al.
Medrxiv : the Preprint Server for Health Sciences|June 17, 2024
Predictors and Risk Score for Immune Checkpoint-Inhibitor-Associated Myocarditis SeverityJohn R Power, Charles Dolladille, Benay Ozbay, et al.
JACC. Cardiooncology|April 17, 2025
Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic DysfunctionYen-Chou Chen, Charles Dolladille, Anjali Rao, et al.
European Heart Journal|June 26, 2025
Immune checkpoint inhibitor-associated myocarditis: a novel risk scoreJohn R Power, Charles Dolladille, Benay Ozbay, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal for Immunotherapy of Cancer|September 13, 2022
Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)Rick Daniel Vavolizza, Gina R Petroni, Ileana S Mauldin, et al.
Oncoimmunology|April 2, 2021
A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanomaCraig L Slingluff, Hassane M Zarour, Hussein Abdul-Hassan Tawbi, et al.
Journal for Immunotherapy of Cancer|January 22, 2021
Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63)Craig L Slingluff, Gina R Petroni, Kimberly A Chianese-Bullock, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC)Emily K Ninmer, Gina R Petroni, Brian R Gastman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2018
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic MelanomaDouglas B Johnson, Jennifer Bordeaux, Ju Young Kim, et al.
Journal for Immunotherapy of Cancer|March 5, 2026
Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review studyElizabeth M Gaughan, Miso Kim, Ignacio Mendez, et al.
Medrxiv : the Preprint Server for Health Sciences|June 17, 2024
Predictors and Risk Score for Immune Checkpoint-Inhibitor-Associated Myocarditis SeverityJohn R Power, Charles Dolladille, Benay Ozbay, et al.
JACC. Cardiooncology|April 17, 2025
Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic DysfunctionYen-Chou Chen, Charles Dolladille, Anjali Rao, et al.
European Heart Journal|June 26, 2025
Immune checkpoint inhibitor-associated myocarditis: a novel risk scoreJohn R Power, Charles Dolladille, Benay Ozbay, et al.
Pageof 3